Laurie Margolies | Medicine and Health Sciences | Excellence in Research Award

Published on by Research Hypothesis

Dr. Laurie Margolies | Medicine and Health Sciences | Excellence in Research Award

Dr. Laurie Margolies | Medicine and Health Sciences | Excellence in Research Award | MD | Icahn School of Medicine at Mount Sinai | United States

Dr. Laurie Margolies is a distinguished radiologist and internationally respected leader in breast imaging, currently serving as Professor and Vice Chair for Breast Imaging in the Department of Diagnostic, Molecular, and Interventional Radiology at the Icahn School of Medicine at Mount Sinai, where she has made transformative contributions to breast cancer detection, digital imaging, and women’s health. Dr. Laurie Margolies completed her undergraduate studies in Biomedical Ethics at Brown University, earned her medical degree from Yale University School of Medicine, and pursued advanced clinical training through an internal medicine internship at Griffin Hospital, a radiology residency at Columbia-Presbyterian Medical Center, and a comprehensive fellowship in CT, ultrasound, and MRI at Yale University/Yale New Haven Hospital. Her professional experience spans decades of academic appointments, including Instructor at Yale, rising through faculty ranks at Mount Sinai from Assistant Professor to full Professor, while simultaneously serving as System Chief of Breast Imaging across multiple hospitals, Director of Breast Imaging at Mount Sinai Hospital, and Chief of Breast Imaging at the Dubin Breast Center. Dr. Laurie Margolies’s research interests center on breast cancer screening optimization, digital mammography, cardiovascular risk evaluation through mammographic arterial calcifications, health disparity reduction, culturally targeted education programs, imaging physics, AI-driven diagnostic tools, and cross-disciplinary cancer detection methods. Her research skills include expertise in multimodality breast imaging, tomosynthesis assessment, radiologic quality control, population-based screening program development, clinical guideline evaluation, and participation in collaborative research teams across oncology, epidemiology, psychology, and medical physics. She has contributed to impactful studies published in reputable journals such as the Journal of Breast Imaging, Clinical Imaging, Journal of Cancer Education, and PEC Innovation, and she has served on multiple advisory boards for leading medical technology companies, advancing AI-assisted imaging development. Dr. Laurie Margolies has received numerous honors, including Fellowship in the American College of Radiology, Fellowship in the Society of Breast Imaging, multiple RSNA Merit Awards, Mount Sinai Innovation Awards, Clinical Imaging Outstanding Reviewer recognition, and repeated selection as a Castle Connolly Top Doctor. She has served on key institutional committees, leadership panels, and mentoring programs, significantly shaping radiologic quality improvement and cancer screening strategies. Dr. Laurie Margolies continues to influence clinical practice through her dedication to research, patient-centered care, and educational advancement, embodying excellence in academic radiology and demonstrating ongoing potential to elevate global breast imaging standards.

Profile: ORCID | Google Scholar

Featured Publications 

  1. Margolies, L. R., Spear, G. G., Payne, J. I., Iles, S. E., & Abdolell, M. (2025). Artificial intelligence for assessment of digital mammography positioning reveals persistent challenges.

  2. Rossi, J., Cho, L., Newell, M. S., Venta, L. A., Montgomery, G. H., Destounis, S. V., Brem, R. F., Parghi, C., & Margolies, L. R. (2025). Breast arterial calcifications on mammography: A review of the literature.

  3. Mullen, L. A., Ambinder, E. B., Talati, N., & Margolies, L. R. (2023). Mammography information systems: A survey of breast imaging radiologist satisfaction and perspectives.

  4. Head, K. J., Harrington, N. G., Schnur, J. B., Margolies, L., & Montgomery, G. H. (2022). Examining gain- and loss-framed messages in a novel breast cancer screening/cardiovascular context: Does framing matter.

  5. Vang, S., Margolies, L. R., & Jandorf, L. (2022). Screening mammogram adherence in medically underserved women: Does language preference matter.

  6. Fung, J., Vang, S., Margolies, L. R., Li, A., Blondeau-Lecomte, E., Li, A., & Jandorf, L. (2021). Developing a culturally and linguistically targeted breast cancer educational program for a multicultural population.

  7. Margolies, L. R., Salvatore, M., Yip, R., Tam, K., Bertolini, A., Henschke, C., & Yankelevitz, D. (2018). The chest radiologist’s role in invasive breast cancer detection.

 

Nader Genedy | Medical Hypotheses | Best Researcher Award

Published on by Research Hypothesis

Dr. Nader Genedy | Medical Hypotheses | Best Researcher Award

Dr. Nader Genedy | Medical Hypotheses | Best Researcher Award | CRF Cardiology | University Hospital of Wales | United Kingdom 

Dr. Nader Genedy is an accomplished clinician–researcher whose work spans metabolic medicine, cardiology, geriatric care, and osteoporosis, integrating advanced academic training with extensive frontline clinical experience. Dr. Nader Genedy completed his medical degree at the University of Alexandria and progressed through multiple postgraduate qualifications, including MRCGP, MRCP(UK), MRCP(I), and specialist certification in acute internal medicine, enabling him to contribute meaningfully to both primary and specialist healthcare environments. Professionally, Dr. Nader Genedy serves as a GP with Special Interest in Osteoporosis and Geriatric Medicine, a Senior Research Fellow in Cardiology, and a Metabolic Medicine and Chemical Pathology Registrar, combining metabolic bone services, lipidology, endocrine disorders, and cardiovascular risk research with high standards of patient-centred care. His responsibilities extend to complex elderly care, DXA interpretation, risk-modelling analysis, and participation in multidisciplinary teams addressing metabolic and cardiovascular disorders. His research interests encompass atherosclerotic cardiovascular disease risk prediction, familial hypercholesterolaemia modelling, metabolic bone disease, cardiometabolic ageing, and biochemical diagnostics, with notable contributions to clinical trials such as RSA-PACE and metabolic therapeutics studies. Dr. Nader Genedy possesses advanced research skills, including statistical modelling, Cox regression, calibration analysis, SPSS/R processing, clinical dataset evaluation, and quality-improvement methodology, in addition to curriculum design, postgraduate teaching, and specialist question writing for MRCPUK examinations. His scholarly work includes conference presentations, co-authorship of national hyperlipidaemia management tools, and mentorship for postgraduate medical research candidates. Awards and honours recognising his excellence include the Bill Richmond First Prize from HEART UK, the Unsung Hero Award from the Inherited Metabolic Disease Service, multiple GREATix commendations for exemplary clinical service, and a patient feedback award for outstanding metabolic medicine contributions. Through his integrated roles in clinical care, research leadership, and academic assessment, Dr. Nader Genedy consistently demonstrates a strong commitment to advancing evidence-based practice, enhancing clinical education standards, and improving outcomes for complex elderly and cardiometabolic populations. In conclusion, Dr. Nader Genedy’s multifaceted expertise, dedication to research innovation, and ongoing contributions to both healthcare systems and academic scholarship establish him as a highly impactful medical professional whose work continues to influence patient care, clinical research, and postgraduate medical education.

Profile:  ORCID 

Featured Publications 

  1. Genedy, N., & Zouwail, S. (2025). ApoB/LDL-C discordance as a predictor of atherosclerotic cardiovascular disease in genetically confirmed heterozygous familial hypercholesterolemia: A hypothesis-generating cohort study. Journal of Clinical Lipidology.

  2. Genedy, N. (2024). Risk-modelling approaches for residual ASCVD in familial hypercholesterolaemia: An integrative clinical dataset analysis. Cardiometabolic Research Insights.

  3. Genedy, N. (2024). Metabolic bone disease assessment in primary care: Evaluating DXA utilisation and therapeutic optimisation. Journal of Osteoporosis and Geriatric Medicine.

  4. Genedy, N. (2023). Clinical implications of biochemical variability in lipidology clinics: A service-evaluation study. International Journal of Metabolic Medicine.

  5. Genedy, N. (2023). Post-CABG haemodynamic assessment: Inter-operator variability between USCOM and transthoracic echocardiography. Cardiovascular Clinical Methods Review.

  6. Genedy, N. (2022). Optimising hyperlipidaemia pathways: A quality-improvement initiative across multidisciplinary teams. British Journal of Clinical Pathway Innovation.

  7. Genedy, N. (2022). Clinical learning through biochemical case commentary: A structured model for postgraduate teaching. Medical Education Practice Journal.

 

Kholoud Alwosaibai | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Dr. Kholoud Alwosaibai | Medicine and Health Sciences | Best Researcher Award

Dr. Kholoud Alwosaibai | Medicine and Health Sciences | Best Researcher Award | Director | King Fahad Specialist Hospital | Saudi Arabia

Dr. Kholoud Alwosaibai is a highly accomplished biomedical scientist, cancer geneticist, and immunotherapy specialist with over fifteen years of progressive experience in translational oncology, molecular medicine, and clinical genomics. She currently serves as the Director of the Biomedical Research Department at King Fahad Specialist Hospital in Dammam, Saudi Arabia, where she leads multiple funded national research programs in cancer genetics and immuno-oncology. Dr. Kholoud Alwosaibai earned her Ph.D. in Cellular and Molecular Medicine from the University of Ottawa, Canada, focusing on cancer therapeutics, and completed advanced postdoctoral training in immuno-oncology at the same institution. Her educational background also includes a Master’s degree in Medical Biotechnology and a Bachelor’s degree with honors in Biology, complemented by postgraduate certifications from the University of Manchester, Harvard Medical School, and the University of California, San Diego, in bioinformatics, cancer omics, and genomics. Professionally, Dr. Alwosaibai has held various leadership positions, including Head of the Research, Development, and Innovation Unit, Program Manager at the Saudi Genome Satellite Center, and Founder and Vice President of the DAEM Society for Oncology Research. Her research interests span cancer genetics, molecular diagnostics, CAR-T cell therapy, and CRISPR-based genome editing, with a strong focus on precision medicine and the clinical translation of genomic data. Dr. Kholoud Alwosaibai possesses an advanced skill set in next-generation sequencing, cancer variant interpretation, bioinformatics, cellular therapy development, and stem cell research, making her a recognized expert in translational and clinical biomedical research. She has published extensively in high-impact, peer-reviewed journals indexed in Scopus, PubMed, and Web of Science, contributing to global advancements in cancer biology and immunotherapy. Her collaborative work has been featured in leading journals such as Scientific Reports, BMC Cancer, Experimental and Therapeutic Medicine, and Oncotarget. Among her notable recognitions are national research grant awards from the Saudi National Institutes of Health and Sanad Society, as well as an award of excellence from the Saudi Arabian Cultural Bureau in Canada for her outstanding doctoral research performance. Throughout her career, Dr. Kholoud Alwosaibai has demonstrated a strong commitment to mentorship, scientific integrity, and capacity building in Saudi Arabia’s biomedical research landscape. Her visionary leadership, innovative research initiatives, and dedication to developing genomic medicine infrastructure position her as an influential figure in advancing cancer research and personalized therapeutics. In conclusion, Dr. Kholoud Alwosaibai’s professional journey reflects a rare blend of scientific excellence, leadership, and global collaboration, making her an inspiring model for emerging scientists and a driving force for the future of precision oncology and genomic innovation.

Profile: Scopus | ORCID

Featured Publications 

  1. Alwosaibai, K., Abedini, A., Al-Hujaily, E. M., Tang, Y., Garson, K., Collins, O., & Vanderhyden, B. C. (2017). PAX2 maintains the differentiation of oviductal epithelium and inhibits the transition to a stem cell-like state. Oncotarget. Citations: 85

  2. Gharaibeh, L., Elmadany, N., Alwosaibai, K., & Alshaer, W. (2020). Notch 1 in cancer therapy: Possible clinical implications and challenges. Molecular Pharmacology. Citations: 64

  3. Ghandorah, S., & Alwosaibai, K. (2021). Post-liver transplantation GVHD: Time to consider histocompatibility testing. Journal of Liver Transplantation. Citations: 22

  4. Alwosaibai, K., Al-Hujaily, E. M., Alamri, S., Ghandorah, S., Garson, K., & Vanderhyden, B. C. (2022). PAX2 induces vascular-like structures in normal ovarian cells and ovarian cancer. Experimental and Therapeutic Medicine, 23(6), 412. Citations: 37

  5. Alwosaibai, K., Aalmri, S., Mashhour, M., Ghandorah, S., Alshangiti, A., Azam, F., Selwi, W., Gharaibeh, L., Alatawi, Y., Alruwaii, Z., & Alsaab, H. O. (2023). PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markers. BMC Cancer, 23(1), 13. Citations: 41

  6. Alessy, S. A., Almotlak, A. A., Alattas, M., Alshareef, A., Alwosaibai, K., Alghamdi, M. A., Razack, H. I. A., & Alqahtani, S. A. (2024). Cancer research challenges and potential solutions in Saudi Arabia: A qualitative discussion group study. JCO Global Oncology, 10, e2300189. Citations: 18

  7. Alwosaibai, K., Alruwaii, Z. I., Mashhour, M., Almsned, F. M., Asraf, R., Alrsheedy, W., Alessa, A., Almohanna, H., Selwi, W., & Azam, F. (2024). Dysgerminomas: Germ cell tumors exhibit high expression of PD-L1 and are associated with high TILs and good prognosis. Scientific Reports, 14(1), 24191. Citations: 12

 

Tianhui Yuan | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Prof. Dr. Tianhui Yuan | Medicine and Health Sciences | Best Researcher Award

Associate Director | The First Affiliated Hospital of Guangzhou University of Medicine | China

Prof. Dr. Tianhui Yuan is a distinguished physician-scientist whose educational journey culminated in the M.D. and a Ph.D. in integrated medicine and cardiovascular science (with doctoral training at a leading university), and she currently serves as Chief Physician, Doctoral Supervisor, and Associate Director of her department while also holding a Visiting Scholar appointment in the United States. Over her career, she has held progressive roles in clinical practice, laboratory research, and academic leadership in integrative Chinese and Western medicine. Her professional experience spans directing clinical care units in cardiovascular medicine, mentoring doctoral and postdoctoral researchers, coordinating international research collaborations, and representing her institution in health policy and traditional medicine networks. Her research interests lie at the interface between traditional Chinese medicine and modern cardiovascular disease therapy, particularly focusing on mechanisms and therapeutic strategies for heart failure, cardiomyopathy, coronary artery disease, hypertension, arrhythmia, hyperlipidemia, and insomnia. She is skilled in experimental cardiovascular physiology, molecular biology, signaling pathway analysis, preclinical animal models, translational interventions, and clinical guideline development. She has made significant scholarly contributions: she has authored 15 documents, received 154 Citations, and holds an h-index of 7, reflecting a growing impact. Among her honors and awards, she has been selected for the Guangdong Provincial Health Commission’s “Guangdong Special Support Program” and the “Youth Talent Support Program,” and she holds recognition as a young academic leader at her university; she also serves on multiple national and international professional committees and has contributed to guideline development, patent filing (2 invention patents), software intellectual property (1 software copyright), and the authorship of 9 books. Through mentorship she has guided student teams to high distinction in innovation competitions and has been invited as a keynote speaker at major conferences like the ESC Heart Failure Congress and the International Heart Congress. Given her solid educational foundation, extensive clinical and research experience, integrative medicine focus, leadership roles, and peer-recognized contributions, Prof. Dr. Tianhui Yuan is exceptionally well positioned to advance her field further, strengthen international collaborations, expand high-impact publication outputs, and mentor the next generation of integrative cardiovascular researchers.

Profile: Scopus

Featured Publications

  1. Ma, X., … Yuan, T. (2023). Regulation of phospholipid peroxidation signaling by a traditional Chinese medicine formula to prevent myocardial ischemia. Journal Name.

  2. Dong, X., Han, X., Zhang, X., … Yuan, T. (2022). A simplified herbal formula improves cardiac function and reduces inflammation in mice through the TLR-mediated NF-κB signaling pathway. Journal Name.

  3. Yang, Z., Xian, S., Yuan, T. (2020). Dexmedetomidine-mediated regulation of miR-17-3p in H9C2 cells after hypoxia/reoxygenation injury. Journal Name.

  4. Yuan, T., Chen, Y., Zhou, X., … (2019). Effectiveness and safety of Danshen injection on heart failure: protocol for a systematic review and meta-analysis. Journal Name.

  5. Wang, L., Gao, M., Chen, J., … (2015). Resveratrol ameliorates pressure overload-induced cardiac dysfunction and attenuates autophagy in rats. Journal Name.